Alcon News
Most Popular Alcon Story
Novartis pledges $39B for Alcon
In a bid to diversify its business away from traditional pharma, Novartis has bought a 25 percent stake in Alcon and is eyeing the purchase of another 52 percent in 2010. The Swiss drugmaker paid... Read more...
Latest Headlines
- February 12, 2010
- February 3, 2010
- January 20, 2010
- January 15, 2010
- January 12, 2010
- January 5, 2010
- January 4, 2010
- December 30, 2009
- December 3, 2009
- June 15, 2009
- June 3, 2009
- July 8, 2008
- May 20, 2008
- April 15, 2008
- April 14, 2008
- April 9, 2008
- April 8, 2008
- April 7, 2008
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
